Articles published by ReCode Therapeutics

ReCode Therapeutics Announces New Funding from the Cystic Fibrosis Foundation, Collaboration with a Leading Gene Editing Company and Leadership Transition

August 06, 2026

From ReCode Therapeutics

Via Business Wire

ReCode Therapeutics Achieves a First: Proof of Activity in Primary Ciliary Dyskinesia Patients

May 20, 2026

From ReCode Therapeutics

Via Business Wire

ReCode Therapeutics Initiates Enrollment of Phase 2 Clinical Trial of RCT2100 in Combination with Ivacaftor for the Treatment of Cystic Fibrosis

November 17, 2025

From ReCode Therapeutics

Via Business Wire

ReCode Therapeutics Announces Over $29 Million in Additional Financing to Advance Genetic Medicines Pipeline and Provides Corporate Update

September 29, 2025

From ReCode Therapeutics

Via Business Wire

ReCode Therapeutics Receives U.S. FDA Orphan Drug Designation for RCT2100 for the Treatment of Cystic Fibrosis

March 25, 2025

From ReCode Therapeutics

Via Business Wire

ReCode Therapeutics Announces Additional Funding From the Cystic Fibrosis Foundation to Accelerate Development of Novel Gene Correction Therapeutics to Treat Cystic Fibrosis

November 18, 2024

From ReCode Therapeutics

Via Business Wire

ReCode Announces Two Key Additions to Scientific Advisory Board

October 01, 2024

From ReCode Therapeutics

Via Business Wire

ReCode Therapeutics Presents Preclinical Data from its Cystic Fibrosis Program at the 2024 North American Cystic Fibrosis Conference (NACFC) in Boston

September 26, 2024

From ReCode Therapeutics

Via Business Wire

ReCode Therapeutics Doses First Patient in Phase 1b Clinical Study of RCT2100 for the Treatment of Cystic Fibrosis

September 26, 2024

From ReCode Therapeutics

Via Business Wire

ReCode Therapeutics to Participate in Upcoming Investor Conferences

September 25, 2024

From ReCode Therapeutics

Via Business Wire

ReCode Therapeutics Receives U.S. FDA Orphan Drug Designation for RCT1100 for the Treatment of Primary Ciliary Dyskinesia

June 27, 2024

From ReCode Therapeutics

Via Business Wire

New Article Published in Science Highlights the Potential of ReCode Therapeutics’ Systemic Lung Delivery and CFTR Gene Correction

June 13, 2024

From ReCode Therapeutics

Via Business Wire

ReCode Therapeutics Announces Appointment of Dean J. Mitchell as Chairman of Its Board of Directors

May 13, 2024

From ReCode Therapeutics

Via Business Wire

ReCode Therapeutics to Participate in May Conferences

May 01, 2024

From ReCode Therapeutics

Via Business Wire

ReCode Therapeutics Announces First Participants Dosed in a Phase 1 Healthy Volunteer Clinical Study of Inhaled mRNA-Based Genetic Medicine, RCT2100, for the Treatment of Cystic Fibrosis

February 21, 2024

From ReCode Therapeutics

Via Business Wire

ReCode Therapeutics to Participate in February Conferences

February 20, 2024

From ReCode Therapeutics

Via Business Wire

Intellia Therapeutics and ReCode Therapeutics Announce Strategic Collaboration to Develop Novel Gene Editing Therapies for Cystic Fibrosis

February 15, 2024

From ReCode Therapeutics

Via Business Wire

Tickers NTLA

ReCode Therapeutics Doses First Patient in Phase 1 Clinical Study of Novel mRNA-based Therapy for the Treatment of Primary Ciliary Dyskinesia

January 03, 2024

From ReCode Therapeutics

Via Business Wire

ReCode Therapeutics to Participate in November Conferences

November 10, 2023

From ReCode Therapeutics

Via Business Wire

ReCode Therapeutics Announces Closing of Extension to Series B Financing

September 19, 2023

From ReCode Therapeutics

Via Business Wire

ReCode Therapeutics to Present at September Investor Conferences

September 07, 2023

From ReCode Therapeutics

Via Business Wire

ReCode Therapeutics Appoints Erica Jefferson as Senior Vice President of Corporate Affairs

July 10, 2023

From ReCode Therapeutics

Via Business Wire

ReCode Therapeutics to Present at Jefferies Healthcare Conference

June 02, 2023

From ReCode Therapeutics

Via Business Wire

ReCode Therapeutics Appoints John G. Matthews, MBBS, MRCP, Ph.D., as Senior Vice President, Clinical Development

April 17, 2023

From ReCode Therapeutics

Via Business Wire

ReCode Therapeutics to Present at Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Days

March 27, 2023

From ReCode Therapeutics

Via Business Wire

ReCode Therapeutics to Present at BMO Biopharma Spotlight Series: Novel Technologies for the Delivery of Genetic Medicines

March 21, 2023

From ReCode Therapeutics

Via Business Wire

ReCode Therapeutics Announces First Participants Dosed in a Phase 1 Healthy Volunteer Clinical Trial of Novel Disease-Modifying Genetic Medicine, RCT1100 for the Treatment of Primary Ciliary Dyskinesia

March 15, 2023

From ReCode Therapeutics

Via Business Wire

Recode Therapeutics Expands Leadership Team with Appointment of April Loui as Senior Vice President of Quality and CMC Regulatory Affairs

February 01, 2023

From ReCode Therapeutics

Via Business Wire

ReCode Therapeutics Announces Strategic Investment from the Cystic Fibrosis Foundation to Accelerate Development of Novel mRNA Therapy

January 10, 2023

From ReCode Therapeutics

Via Business Wire

ReCode Therapeutics Announces Strategic Collaboration with AskBio to Explore Single Vector Gene-Editing Platform

January 09, 2023

From ReCode Therapeutics

Via Business Wire

< Previous 1 2 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.